Daniel J. Drucker, MD

Adults with type 2 diabetes assigned a novel dual GIP/GLP-1 receptor agonist for 40 weeks experienced significant reductions in HbA1c and body weight compared with those assigned placebo, according to top-line data from the SURPASS-1 study.

Type 1 diabetes does not increase risk for hospitalization from COVID-19, particularly among individuals without diabetes complications, according to an analysis of hospital data.

Evidence suggests hydroxychloroquine may play a role in glucose homeostasis among select individuals with type 2 diabetes; however, data on long-term safety and efficacy are lacking, particularly in the setting of COVID-19.